Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMN28-CARTITUDE-6: DVRd + cilta-cel vs DVRd + ASCT in transplant-eligible newly diagnosed multiple myeloma
jRCT2063220071Phase 3Recruiting
- Sponsor
- European Myeloma Network
- Start
- Aug 2024
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
01
Overview
Phase 3, randomised trial of ciltacabtagene autoleucel in multiple myeloma (MM) (2 arms), sponsored by European Myeloma Network. Primary endpoints: Progression-free survival (PFS) and Sustained MRD-negative complete response. Started Aug 2024; status: recruiting.
02
Drugs
ciltacabtagene autoleucel
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCT2063220071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2063220071.